162 related articles for article (PubMed ID: 24671680)
1. Modification of HSV-1 to an oncolytic virus.
Nakashima H; Chiocca EA
Methods Mol Biol; 2014; 1144():117-27. PubMed ID: 24671680
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpes simplex virus engineering and preparation.
Agarwalla PK; Aghi MK
Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.
Jeyaretna DS; Kuroda T
Curr Opin Mol Ther; 2007 Oct; 9(5):447-66. PubMed ID: 17932809
[TBL] [Abstract][Full Text] [Related]
5. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
7. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
8. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
Kahramanian A; Kuroda T; Wakimoto H
Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
10. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
Kuroda T; Martuza RL; Todo T; Rabkin SD
BMC Biotechnol; 2006 Sep; 6():40. PubMed ID: 16995942
[TBL] [Abstract][Full Text] [Related]
11. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
Ino Y; Saeki Y; Fukuhara H; Todo T
Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
[TBL] [Abstract][Full Text] [Related]
12. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
13. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
14. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
Long Y; Mi Y; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control.
Simpson GR; Coffin RS
Methods Mol Biol; 2009; 542():551-64. PubMed ID: 19565922
[TBL] [Abstract][Full Text] [Related]
16. Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.
Enow JA; Sheikh HI; Rahman MM
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005938
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
18. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
19. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
Bauzon M; Hermiston TW
Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
[TBL] [Abstract][Full Text] [Related]
20. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.
Nawa A; Luo C; Zhang L; Ushjima Y; Ishida D; Kamakura M; Fujimoto Y; Goshima F; Kikkawa F; Nishiyama Y
Curr Gene Ther; 2008 Jun; 8(3):208-21. PubMed ID: 18537595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
